Boston Scientific

Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

The company is known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. The company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator (ICD) called the EMBLEM subcutaneous implantable defibrillator (S-ICD).

Over the last 20 years, Boston Scientific has had some high-profile patent infringement cases. It has made extensive payouts, including $1.725 billion to Johnson & Johnson, $85 million to Nevro and $42 million to TissueGen.

BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware.

History

Boston Scientific was formed on June 29, 1979, in Watertown, Massachusetts, as a holding company for the medical products company Medi-Tech, Inc., and to position the company for growth in interventional medicine. Medi-Tech was the brainchild of Itzhak Bentov, a Czech-born émigré to Israel and then to the United States, who worked at the Arthur D. Little think tank in Cambridge, Massachusetts, and ran a contract research company from his rented house in Belmont, Massachusetts, a venture he founded in 1965 with a business friend, Dan Singer.

After a decade of steady growth, Abele met Pete Nicholas by chance in their neighborhood in Concord, Massachusetts. Their partnership hinged on Nicholas' goal to build business enterprises and Abele's predilection for the vision and potential in noninvasive surgical instrumentation; they gathered backers in the Boston banking community to buy out the Cooper Labs interest and form the new corporation.

Initial public offering (1992)

On May 19, 1992, Boston Scientific launched an initial public offering of 23.5 million shares, of which 18.8 million were offered in the U.S. and 4.7 million were offered outside the U.S. The initial offering amounted to 23% of Boston Scientific's outstanding stock. The U.S. shares were listed on the New York Stock Exchange.

Post–IPO

thumb|[[Drug-eluting stent|TAXUS™ Paclitaxel-Eluting Coronary Stent]]

From 1995 through 1997, Boston Scientific increased its technology R&D and product offerings following substantial acquisitions that included Cardiovascular Imaging Systems (intravascular ultrasound), SCIMED (cardiovascular), Vesica Medical (urology), Meadox (textile vascular prostheses), EP Technologies (cardiac ablation controllers), MinTec (abdominal aortic aneurysm grafts), Symbiosis Corporation (specialty medical product manufacture).

On November 3, 1998, Boston Scientific restated its financial results for 1997, as well as its quarterly results for the first three quarters of 1998, due to the occurrence of business irregularities in the operations of its Japanese subsidiary.

In 2001, Boston Scientific acquired Target Therapeutics (neurology) in a tax-free stock swap for about $1.1 billion, more than 10 times Target's total sales, in contrast to the usual multiple of 10 times earnings.

The Taxus Stent was approved in 2003 in Europe and other countries and, in the United States, by the FDA in March 2004. It was the second drug-eluting stent approved in the United States.

In April 2004, the company announced that it had exercised an exclusive option to acquire Precision Vascular Systems, Inc., as part of a series of agreements between Boston Scientific and Precision Vascular in 2002, for an undisclosed sum. In June, Boston Scientific acquired Advanced Bionics Corporation for $740 million in cash, plus earn out payments. In December, Boston Scientific completed its acquisition of Advanced Stent Technologies, Inc., for $120 million payable in Boston Scientific stock, plus the possibility of future contingent payments. AST had been developing stent and stent delivery systems specifically designed to address the anatomical needs of coronary artery disease in bifurcated vessels. In June Boston Scientific announced that its wholly owned subsidiary, Nemo I Acquisition, Inc., had successfully acquired Salt Lake City-based Rubicon Medical Corporation, with Rubicon became a wholly owned subsidiary of Boston Scientific.

Guidant merger

In January 2006, the company announced an offer for its longtime competitor, Guidant, for $72 per share or $25 billion. The offer, however, was rejected. On April 21, 2006, BSC acquired Guidant for $27.2 billion.

Post-merger

In December 2007, Boston Scientific announced it would sell its Fluid Management and Venous Access businesses for $425 million to Avista Capital Partners.

In April 2008, the company acquired CryoCor, Inc., for $1.35 per share, $17.6 million in total. Navilyst Medical was formed in February 2008 from Boston Scientific's Fluid Management and Vascular Access business units.

In January 2009, Boston announced it would acquire Labcoat Limited, whose primary development was that of a development-stage drug-eluting stent – for an undisclosed sum.

2010–2020

In October 2010, the company was fined $600,000 by the US Department of Justice for paying a US Army doctor to use their devices and recommend them to others. In the same month Boston Scientific acquired Asthmatx, Inc., for $193.5 million, with payments of up to $250 million being paid on the achievement of specified revenue-based criteria through 2019.

In January 2011, Boston acquired Atritech, Inc., for $100 million plus additional potential payments of up to $275 million. In September, the company announced it would acquire BridgePoint Medical, Inc., developer of a catheter-based system to treat coronary chronic total occlusions. In October, the company acquired Rhythmia Medical, Inc., developer of mapping and navigation methods for use in cardiac catheter ablations and other electrophysiology procedures. A month later, the business acquired catheter-based renal denervation system developer, Vessix Vascular, Inc.

In November 2013, Boston announced it would acquire Bard EP, the electrophysiology business of C.R. Bard, Inc. for $275 million.

In May 2014, Boston acquired hysteroscopic intrauterine tissue removal specialist, IoGyn, Inc. In September, the business announced it would acquire the Interventional business of Bayer.

In March 2015, the company announced it would acquire Endo International Plc's American Medical Systems urology business for at least $1.6 billion, expanding the company's health and prostate treatments. In April, Boston announced its intention to acquire Xlumena, Inc. In October Boston announced it had invested further in percutaneous mitral valve replacement system developer, MValve Technologies, gaining a right to acquire the business in the future.

In July 2016, the business acquired the manufacturer of radiofrequency ablation systems, Cosman Medical, Inc. In September, Boston Scientific announced it had acquired EndoChoice Holdings, Inc., becoming part of the Boston Scientific Endoscopy business for $210 million. In November, the company acquired the gynecology and urology portfolio of Distal Access, LLC, a company that designs minimally invasive medical devices. In December 2016, the business acquired a 15% stake in Neovasc, Inc., for $75 million.

In 2016, Boston Scientific acquired EndoChoice, located in Alpharetta, Georgia.

In May 2017, the company acquired Symetis SA, a developer of minimally invasive transcatheter aortic valve implantation devices. In October, Boston acquired Apama Medical Inc. for up to $300 million.

In April 2018, Boston Scientific announced the triple closure of its acquisitions of women's health company, nVision Medical Corporation, NxThera and Securus Medical Group, Inc., for up to $50 million. In July, Boston Scientific announced it would acquire Cryterion Medical, Inc, Veniti, Inc., in August Augmenix, Inc., and Claret Medical, Inc. In November, Boston Scientific announced it would acquire UK medical device maker BTG plc for $4.2 billion. In late December, the company announced it would acquire Millipede, Inc for $325 million, after previously investing $90 million in the company.

In May 2019, the company announced it would acquire Vertiflex, Inc., with the aim of increasing its interventional pain therapy offerings. Vertiflex principally developed treatment for lumbar spinal stenosis.

2021–present

In January 2021, Boston announced it would acquire Minneapolis-based Preventice Solutions, Inc., and its portfolio of mobile cardiac health solutions for up to $1.2 billion. In March, the business announced it would acquire the surgical business part of Lumenis Ltd. for $1 billion from an affiliate of Baring Private Equity Asia, who, in 2019, had acquired Lumenis from XIO Group. In June, the company announced it would acquire the 73% of Farapulse, Inc., it did not already own, for $295 million. Farapulse was a University of Iowa startup. The deal complimented Boston Scientific's existing electrophysiology portfolio. In September, the business announced it would acquire Devoro Medical, Inc., and its blood clot capturing technology. Boston Scientific had been a strategic investor in Devoro since 2019. In October, the company announced it would acquire Baylis Medical Company Inc. for $1.75 billion, expanding its electrophysiology and heart product portfolios (see Frank Baylis).

In June 2022, the Boston Scientific announced it would acquire M.I.Tech Co., Ltd., of South Korea, for around $230 million. The deal was cancelled in May 2023 citing regulatory hurdles. In August, Boston announced it would acquire Obsidio, Inc.

In June 2022, Boston Scientific announced that it would invest $62.5 million in a manufacturing and supply chain facility in Johns Creek, Georgia, a suburb of Atlanta.

In September 2023, Boston Scientific acquired Relievant Medsystems, Inc. for an upfront cash payment of $850 million and undisclosed additional contingent payments based on sales performance over the next three years.

In January 2024, the company announced it would acquire Axonics, Inc. for $3.7 billion.

In January 2026, Boston Scientific announced it would acquire Penumbra in a ~$15 billion cash and stock deal. The deal was expected to close by yearend.

Corporate governance

Michael F. Mahoney is the current Boston Scientific chairman and chief executive officer.

{| class="wikitable"

| valign="top" |Board Member

| valign="top" |Role

| valign="top" |Michael F. Mahoney

| valign="top" |Chairman and Chief Executive Officer

| valign="top" |Yoshiaki Fujimori

| valign="top" |Director

| valign="top" |David Habiger

| valign="top" |Director

| valign="top" |Jessica L. Mega

| valign="top" |Director

| valign="top" |Susan E. Morano

| valign="top" |Director

| valign="top" |Edward J. Ludwig

| valign="top" |Director

| valign="top" |Cheryl Pegus

| valign="top" |Director

| valign="top" |Cathy R. Smith

| valign="top" |Director

| valign="top" |John E. Sununu

| valign="top" |Director

| valign="top" |Christophe P. Weber

| valign="top" |Director

| valign="top" |David S. Wichmann

| valign="top" |Director

| valign="top" |Ellen M. Zane

| valign="top" |Director

{| class="wikitable"

| valign="top" |Executive

| valign="top" |Role

| valign="top" |Michael F. Mahoney

| valign="top" |Chairman and Chief Executive Officer

| valign="top" |Vance R. Brown

| valign="top" |Executive Vice President, General Counsel and Corporate Secretary

| valign="top" |Arthur C. Butcher

| valign="top" |Executive Vice President and Group President, MedSurg and Asia Pacific

| valign="top" |Joeseph M. Fitzgerald

| valign="top" |Executive Vice President and Group President, Cardiovascular

| valign="top" |Jonathan R. Monson

| valign="top" |Executive Vice President and Chief Financial Officer

| valign="top" |Miriam O’Sullivan

| valign="top" |Senior Vice President, Chief Human Resources Officer

| valign="top" |Paudie O’Connor

| valign="top" |Executive Vice President, Global Operations

Organizational culture

Bloomberg recognized BSC for its inclusion in the Gender-Equality Index in 2019, which includes companies that publicly demonstrate their commitment to equality and the advancement of women in the workplace. The index lists a total of 230 companies from ten economic sectors and 36 countries and regions.
The Human Rights Campaign ("HRC") named BSC as a Best Place to Work for LGBTQ Equality in its 2019 edition of the eponymous list. HRC has given BSC a ranking of 100 (of 100) every year from 2015 through 2021 in its annual CEI Index (Corporate Equality Index) rankings of Fortune 1000 companies.
The journal US Black Engineer & Information Technology (USBE & IT), in its "2021 Top Supporters of HBCU Engineering," ranked BSC No. 6 among the "Top 20 Industry Supporters."

Financials

{| class="wikitable"

|Year

|Revenue in mil. US

|Net income in mil. US

|Assets in mil. US

|Employees

| valign="top" |2016

| valign="top" |8,386

| valign="top" |347

| valign="top" |18,096

| valign="top" |27,000

| valign="top" |2017

| valign="top" |9,048

| valign="top" |104

| valign="top" |19,042

| valign="top" |29,000

| valign="top" |2018

| valign="top" |9,823

| valign="top" |1,671

| valign="top" |20,999

| valign="top" |32,000

| valign="top" |2019

| valign="top" |10,735

| valign="top" |4,700

| valign="top" |30,565

| valign="top" |36,000

| valign="top" |2020

| valign="top" |9,913

| valign="top" |-115

| valign="top" |30,777

| valign="top" |38,000

| valign="top" |2021

| valign="top" |11,888

| valign="top" |985

| valign="top" |32,229

| valign="top" |41,000

| valign="top" |2022

| valign="top" |12,682

| valign="top" |642

| valign="top" |32,469

| valign="top" |45,000

| valign="top" |2023

| valign="top" |14,240

| valign="top" |1,592

| valign="top" |35,136

| valign="top" |48,000

| valign="top" |2024

| valign="top" |16,747

| valign="top" |1,846

| valign="top" |39,395

| valign="top" |53,000

| valign="top" |2025

| valign="top" |20,074

| valign="top" |2,892

| valign="top" |43,673

| valign="top" |59,000

Litigation

Johnson & Johnson patent litigation

Beginning in 2003, Boston Scientific and Johnson & Johnson were involved in a series of litigations involving patents covering heart stent medical devices. Both parties claimed that the other had infringed upon their patents. The litigation was settled once Boston Scientific agreed to pay $716 million to Johnson & Johnson in September 2009 and an additional $1.73 billion in February 2010.

It was announced in November 2014 that Johnson & Johnson would have another chance for payback after a multibillion-dollar trial was set for November 20, 2014. A New York federal court judge would hear the case without a jury to decide whether Boston Scientific should be held liable for the contract breach.

Transvaginal mesh

Boston Scientific is one of several manufacturers of a medical device called transvaginal mesh, a type of surgical mesh used to treat pelvic organ prolapse. Experts concluded that the medical company had used cheap, counterfeit resin, which was both toxic and degraded when exposed to oxygen. When this was announced on 60 Minutes, Boston Scientific responded by saying the broadcast was "irresponsible and misleading," citing a 2017 Food and Drug Administration (FDA) report stating that although they found variability in the polypropylene resin, "these differences do not present new safety or effectiveness concerns." One woman, who sued in 2011, was awarded $100 million. Two operations had failed to remove all the parts of the mesh and she was still in pain. The company appealed the decision and had the amount reduced to $10M. On March 23, 2021, the company agreed to pay $189 million to settle allegations that it had seriously misrepresented the risks related to the vaginal mesh. As of Jan. 27, 2021, around 54,000 lawsuits related to transvaginal meshes had been filed against Boston Scientific.

In April 2019, the FDA ordered Boston Scientific and Coloplast to remove all of their vaginal mesh products from the United States market. In 2020, Johnson & Johnson was required to pay $344 million for failing to disclose the serious product risks of its transvaginal mesh product.

NIR stent

In 2005, Boston Scientific paid $74 million to settle allegations that it had continued to sell NIR stents (flexible stents) after learning that many of them were defective. Twenty-six injuries and one death may have been caused by malfunctioning stents.

Defective defibrillators

thumb|Guidant Vitalilty™ AVT™ implantable cardioverter-defibrillator – Model A135 (The model illustrated was not the subject of the charge.)

In 2011, Guidant, a subsidiary of Boston Scientific, was criminally convicted of a failure to report defibrillator safety problems to the FDA. The company was forced to pay more than $296 million in criminal fines and had to submit to the supervision of the U.S. Probation Office for three years.

Even though Guidant knew the devices were defective, they continued to sell the defibrillators anyway. Guidant LLC had also advised its sales representatives to tell physicians that nothing was wrong with the defibrillators, and told the FDA that the proposed corrections were not being done to correct life-threatening device flaws, but were rather to improve process throughout. Not until three deaths had occurred and ten months had passed did the company reveal the defects in 2005. The directives for these wrongdoings had been implemented prior to Boston Scientific's acquisition of Guidant in 2006.

In 2013, BSC and three of its subsidiaries – Guidant LLC, Guidant Sales LLC, and Cardiac Pacemakers, Inc. – agreed to pay $30 million to settle allegations that, according to the Justice Department, between 2002 and 2005, Guidant knowingly sold defective heart devices to health care facilities that in turn implanted the devices into Medicare patients.

Bribery allegations

In 2009, Boston Scientific agreed to pay $22 million to settle allegations that its subsidiary Guidant LLC had used kickback schemes to boost sales for its pacemakers (cardiac rhythm management or CRM devices) and defibrillators (implantable cardioverter-defibrillators or ICD devices). Allegedly, Guidant paid doctors between $1,000 and $1,500 each to participate in one of its four post-studies known as RaCE ($1,500), RaCE II ($1,000), RaCE III ($1,000), and MERITS ($1,000).

Obsidio Embolic recall

In April 2024, the FDA announced a recall of Boston Scientific's device Obsidio Embolic, which is used to stop hemorrhaging and excessive bleeding. It has been found that when the device is paired with the aliquot technique, it can lead to bowel ischemia, which can mean longer hospitalization or death for patients.

Notable people

Donald Steven Baim, MD (1946–2009), served Chief Medical and Scientific Officer for Boston Scientific from 2006 until his death in 2009.
Ian Meredith, MD, PhD, AM (born 1956), was Global Chief Medical Officer and Executive Vice President from 2017 to 2023.
Ursula Burns (born 1958), who served as a Member of Boston Scientific's 13-seat Board of Directors since 2002, resigned after being named Chief Executive Officer of the Xerox Corporation, taking effect July 1, 2009, and becoming the first African-American female CEO of a Fortune 500 company.
Kristina M. Johnson (born 1957), PhD, who served as a Member of BSC's Board since May 2006, resigned in May 2009 after being confirmed by the U.S. Senate to serve as Under Secretary in the Department of Energy (see Under Secretary of Energy for Infrastructure & Under Secretary of Energy for Science and Innovation). Johnson was re-elected to BSC's board January 1, 2011, and served in that position until May 2017.
Yoshiaki Fujimori (born 1951), BSC Board Member since July 2016.
James Robert Tobin Jr. (born 1944), President & CEO of BSC from 1999 through 2009.
John Raymond Elliott "Ray" (born 1950), served as a Board Member from September 2007 to 2009, then, in July 2009, re-joined the Board and became President & CEO, a position he held until December 31, 2011. Before, he had served as Chairman of Zimmer Holdings, Inc., from August 6, 2001, to November 30, 2007, and President & CEO from March 20, 2001, to May 2007.

Headquarters and regional centers

World headquarters: Marlborough, Massachusetts
Europe headquarters: Voisins-le-Bretonneux, France